Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Top Cited Papers
- 1 June 2008
- journal article
- practice guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 51 (6), 1403-1419
- https://doi.org/10.1161/hypertensionaha.108.189141
Abstract
Resistant hypertension is a common clinical problem faced by both primary care clinicians and specialists. While the exact prevalence of resistant hypertension is unknown, clinical trials suggest that it is not rare, involving perhaps 20% to 30% of study participants. As older age and obesity are 2 of the strongest risk factors for uncontrolled hypertension, the incidence of resistant hypertension will likely increase as the population becomes more elderly and heavier. The prognosis of resistant hypertension is unknown, but cardiovascular risk is undoubtedly increased as patients often have a history of long-standing, severe hypertension complicated by multiple other cardiovascular risk factors such as obesity, sleep apnea, diabetes, and chronic kidney disease. The diagnosis of resistant hypertension requires use of good blood pressure technique to confirm persistently elevated blood pressure levels. Pseudoresistance, including lack of blood pressure control secondary to poor medication adherence or white coat hypertension, must be excluded. Resistant hypertension is almost always multifactorial in etiology. Successful treatment requires identification and reversal of lifestyle factors contributing to treatment resistance; diagnosis and appropriate treatment of secondary causes of hypertension; and use of effective multidrug regimens. As a subgroup, patients with resistant hypertension have not been widely studied. Observational assessments have allowed for identification of demographic and lifestyle characteristics associated with resistant hypertension, and the role of secondary causes of hypertension in promoting treatment resistance is well documented; however, identification of broader mechanisms of treatment resistance is lacking. In particular, attempts to elucidate potential genetic causes of resistant hypertension have been limited. Recommendations for the pharmacological treatment of resistant hypertension remain largely empiric due to the lack of systematic assessments of 3 or 4 drug combinations. Studies of resistant hypertension are limited by the high cardiovascular risk of patients within this subgroup, which generally precludes safe withdrawal of medications; the presence of multiple disease processes (eg, sleep apnea, diabetes, chronic kidney disease, atherosclerotic disease) and their associated medical therapies, which confound interpretation of study results; and the difficulty in enrolling large numbers of study participants. Expanding our understanding of the causes of resistant hypertension and thereby potentially allowing for more effective prevention and/or treatment will be essential to improve the long-term clinical management of this disorder.Keywords
This publication has 97 references indexed in Scilit:
- Obstructive Sleep Apnea–Dependent and –Independent Adrenergic Activation in ObesityHypertension, 2005
- Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate‐to‐severe reductions in renal functionBlood Pressure, 2005
- Modest Salt Reduction Lowers Blood Pressure in Isolated Systolic Hypertension and Combined HypertensionHypertension, 2005
- Effects of Weight Loss in Overweight/Obese Individuals and Long-Term Hypertension OutcomesHypertension, 2005
- Modafinil Elicits Sympathomedullary ActivationHypertension, 2005
- Primary Aldosteronism and Hypertensive DiseaseHypertension, 2003
- Progressive Hypertension in a Patient With “Incidental” Renal Artery StenosisHypertension, 2002
- Treatment and Control of Hypertension in the CommunityHypertension, 2002
- Resistant HypertensionHypertension, 2002
- The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytomaWorld Journal of Surgery, 1992